These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32098501)

  • 1. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
    Bethel MA; Stevens SR; Buse JB; Choi J; Gustavson SM; Iqbal N; Lokhnygina Y; Mentz RJ; Patel RA; Öhman P; Schernthaner G; Lecube A; Hernandez AF; Holman RR
    Circulation; 2020 Apr; 141(17):1360-1370. PubMed ID: 32098501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
    Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
    Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
    Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
    Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Mentz RJ; Bethel MA; Gustavson S; Thompson VP; Pagidipati NJ; Buse JB; Chan JC; Iqbal N; Maggioni AP; Marso SP; Ohman P; Poulter N; Ramachandran A; Zinman B; Hernandez AF; Holman RR
    Am Heart J; 2017 May; 187():1-9. PubMed ID: 28454792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
    Mentz RJ; Bethel MA; Merrill P; Lokhnygina Y; Buse JB; Chan JC; Felício JS; Goodman SG; Choi J; Gustavson SM; Iqbal N; Lopes RD; Maggioni AP; Öhman P; Pagidipati NJ; Poulter NR; Ramachandran A; Reicher B; Holman RR; Hernandez AF;
    J Am Heart Assoc; 2018 Oct; 7(19):e009304. PubMed ID: 30371301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
    Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.
    Gooding KM; Stevens S; Lokhnygina Y; Giczewska A; Shore AC; Holman RR
    Diabetes Res Clin Pract; 2024 Jun; 212():111685. PubMed ID: 38670496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
    Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
    Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Green JB; Everett BM; Ghosh A; Younes N; Krause-Steinrauf H; Barzilay J; Desouza C; Inzucchi SE; Pokharel Y; Schade D; Scrymgeour A; Tan MH; Utzschneider KM; Mudaliar S;
    Circulation; 2024 Mar; 149(13):993-1003. PubMed ID: 38344820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Davis TME; Giczewska A; Lokhnygina Y; Mentz RJ; Sattar N; Holman RR;
    Cardiovasc Diabetol; 2022 Jun; 21(1):116. PubMed ID: 35761271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.